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New oral anti-coagulant agents including direct factor Xa
inhibitors (anti-Xa) and direct thrombin inhibitors (anti-IIa)
are rapidly entering into clinical practice. These agents
have been recently licensed in many countries for post-
operative prophylaxis of thromboembolic events after total
hip or knee replacement surgery, and they are becoming im-
portant options for long-term anti-coagulation therapy for
venous thromboprophylaxis, or stroke prevention in non-
valvular atrial fibrillation.1 On the one hand, these drugs
are a welcome change for the patients because they seem
to provide reliable anti-thrombotic effects without cumber-
some laboratory testing and food restrictions.1 On the
other hand, the lack of specific antidotes for these agents
poses major challenges in the perioperative care and bleed-
ing management.2 – 4
Anaesthetists and intensivists have previously learnt the
difficulty of managing the balance of haemostasis and
thrombosis through perioperative uses of argatroban, bivalir-
udin, and lepirudin.5 6 While clinical efficacy and relative
safety of new oral anti-coagulants have been demonstrated,
our knowledge remains limited on the management of
bleeding related to these agents.3 4 7 8 It is thus reasonable
to select a potentially useful agent by testing it in a standar-
dized animal bleeding model for haemostatic efficacy.
Indeed, there have been a number of animal studies that
have examined the reversibility of anti-IIa (melagatran and
dabigatran) and anti-Xa (rivaroxaban and edoxaban) using
the factor concentrate, including recombinant activated
factor VII (rFVIIa), factor VIII bypassing agent (FEIBA), and
prothrombin complex concentrate (PCC). The models,
anti-coagulants, and agents are summarized in Table 1.9–18 Al-
though ximelagatran has been withdrawn from market due to
liver toxicity, early experimental data on melagatran (active
metabolite of ximelagatran) remain pertinent as it exerts
anti-IIa kinetics similar to dabigatran.19 Understanding poten-
tial usefulness and limitations of specific experimental models
and agents is important because there is a risk of thrombosis
with such haemostatic intervention in high-risk patients.20 21
Pertinent animal studies of anti-IIa and anti-Xa agents
widely vary in terms of animal types, vascular injury (timing, lo-
cation, and extent), and coagulation tests utilized (Table 1).
These differences might have led to the mixed results in the ef-
ficacy of a specific intervention, and further limit their applic-
ability to human conditions. For example, haemostatic
activity of rFVIIa is critically dependent on exposed tissue
factor (TF) at the site of vascular injury.22 However, TF expres-
sion is a time-limited event23 because locally accumulated
platelets in vivo prevent TF from binding to FVII (Fig. 1). Most
experimental designs involved pre-treating animals with a
haemostatic agent, followed by inducing a vascular injury. It
is likely that the therapeutic window for an intervention is
much narrower in clinical bleeding because haemostatic
agents are only administered after a variable interval after
the vascular injury, and the diagnosis of haemorrhage.3 24
Further, species specificity for anti-coagulants and haemo-
static agents is an important consideration. The dose
necessary to inhibit thrombosis by 50% (ED50) after oral ad-
ministration of rivaroxaban differs from 0.6 to 5 mg kg21 in
rabbits and rats, respectively, in the arteriovenous shunt
model.25 Therapeutic responses to rFVIIa vary among
species as well. The mouse requires much higher rFVIIa
doses (3–10 mg kg21) compared with human and primate
doses (90–270 mg kg21).11 26 Injecting human coagulation
proteins in various species may not only alter coagulation
factor interactions, but also coagulation assay results. The
endogenous thrombin potential could be improved when
human thrombin is generated in rabbit plasma, but haemo-
stasis was not improved in vivo.17 Elevated thrombin–
anti-thrombin (TAT) complex reflects procoagulant responses
in the host animals after rFVIIa, FEIBA, and PCC administra-
tion,9 10 16 18 but prothrombin time (PT) and activated pro-
thrombin time (aPTT) are not suitable for monitoring
anti-IIa and anti-Xa agents, nor for predicting therapeutic
effects of haemostatic agents.27 The latter tests also
exclude dynamic interactions of platelets, coagulation
factors, and inhibitors (anti-IIa or anti-Xa) which take place
in vivo.7 17 Lastly, the location and extent of vascular injury
can be important determinants of experimental outcomes.
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Table 1 Animal models, agents, and doses for anti-Xa and anti-IIa reversal. ‘’, no change; ‘’, decrease; ‘’, increase; IU, international unit; BT, bleeding time; ICH, intracranial haemorrhage;
CFR, cyclic flow reduction (in the carotid artery); PT, prothrombin time; APTT, activated partial thromboplastin time; ECT, ecarin clotting time; WBCT, whole blood clotting time; ACT, activated
clotting time; TT, thrombin time; TAT, thrombin–anti-thrombin complex level; TEM, thromboelastometry; TG, thrombin generation
Model Injury Anticoagulant Agent/dose Endpoints Reference
Rat Tail BT Melagatran FEIBA 25–400 IU kg21 BT, ECT, PT, aPTT Elg and colleagues9
0.5–2.0 mg kg21 h21 rFVIIa 1–10 mg kg21 BT, WBCT, PT
Rat Tail BT Melagatran FEIBA 200 IU kg21 BT, WBCT, aPTT, TAT Elg and colleagues10
0.8 mg kg21+2 mmol kg21 h21 rFVIIa 1 mg kg21 BT, WBCT, aPTT, TAT
PCC 200 IU kg21 BT, WBCT, aPTT, TAT
Rabbit Ear BT Melagatran FEIBA 200 IU kg21 BT, WBCT, aPTT Elg and colleagues10
0.8 mg kg21+2 mmol kg21 h21 rFVIIa 1 mg kg21 WBCT, ACT, aPTT
PCC 200 IU kg21 BT, WBCT, aPTT
Baboon Skin BT, Melagatran FEIBA 100+150 IU kg21 BT, shunt thrombus Gruber and colleagues11
AV shunt 0.6 mg kg21 h21 rFVIIa 90 + 180 mg kg21 BT, no effect on shunt thrombus
Rat Tail BT Dabigatran FEIBA 50 or 100 IU kg21 BT, aPTT van Ryn and colleagues12
0.5 mmol kg21 h21 for 25 min rFVIIa 0.1 or 0.5 mg kg21 BT, aPTT (dose-dependent)
Mouse Tail BT, Dabigatran PCC 100 U kg21 BT,  haematoma expansion Zhou and colleagues13
ICH 4.5 or 9.0 mg kg21 rFVIIa 8.0 mg kg21 No effects on BT or haematoma expansion
Murine plasma 200 ml No effects on BT or haematoma expansion
Mouse Tail transection Dabigatran FEIBA 100 IU kg21 Blood loss, BT, aPTT Lambourne and colleagues14
60 mg kg21 p.o. rFVIIa 3 mg kg21 Blood loss, BT, aPTT
PCC 14.3 IU kg21 Blood loss, BT, aPTT
PCC 14.3 IU kg 21+ rFVIIa 3 mg kg21 Blood loss, BT, aPTT, TT
Rabbit Kidney incision Dabigatran 0.4 mg kg21 PCC 20, 35, 50 IU kg21 Blood loss, BT, PT, aPTT, improved TEM, TG peak
(dose-dependent)
Pragst and colleagues15
Rat Tail BT Rivaroxaban PCC 50 IU kg21 BT, PT, TAT Perzborn and colleagues16
1.3 mg kg21
Rabbit Spleen/liver incision, Rivaroxaban PCC 40 IU kg21 Blood loss, BT, PT, aPTT, improved TEM, CFR Godier and colleagues17
Ear BT, CFR 5 mg kg21 rFVIIa 150 mg kg21 Blood loss, BT, PT, aPTT, improved TEM, lagtime of TG,
CFR
Rat Skin BT Edoxaban FEIBA 50 or 100 IU kg21 BT, PT (dose-dependent) Fukuda and colleagues18
1 mg kg21 h21 rFVIIa 0.3–3 mg kg21 BT, PT, TAT (dose-dependent), no increased venous
thrombus
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PCC concentrates (50–100 IU kg21) have been shown to be
effective against dabigatran by reducing murine intracranial
haematoma expansion induced by collagen injection,13 and
decreasing bleeding after kidney incision in rabbits.15
However, PCC (40 IU kg21) and rFVIIa (150 mg kg21) failed
to decrease bleeding from liver and splenic incisions in
rivaroxaban-treated rabbits.17 FEIBA (250 IU kg21), but not
rFVIIa (270 mg kg21), increased the deposition of thrombus
in the arteriovenous vascular shunt in melagatran-treated
animals.11
In conclusion, pre-clinical animal data on haemostatic
agents for the reversal of anti-Xa and anti-IIa drugs are en-
couraging, but they fail to provide sufficient information on
the optimal timing, dose(s), and efficacy in humans. Given
the lack of clinical evidence of haemostatic agents for
anti-IIa and anti-Xa reversal in a variety of clinical scen-
arios,28 29 the need for rFVIIa, FEIBA, or PCC for patients
with uncontrolled bleeding must be individually assessed
by the treating physician according to the institutional
transfusion guideline and the available consensus.30 It is
also important to combine other available measures (e.g.
activated charcoal, dialysis, topical haemostatics) with i.v.
agents, so that the dose requirement can be minimized for
the latter.
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Fig 1 After the vascular injury, TF and collagen are locally
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prothrombin to increase thrombin generation on the activated
platelet surface. Anti-Xa agents (apixaban, edoxaban, rivaroxa-
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